#VisualAbstract: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Click here to read this study in NEJM.
©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
